Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~I (first step):~* Admission to hospital~* Male or non-pregnant female, ≥60 years of age or ≥30 years of age plus one or more known risk factors (arterial hypertension, diabetes mellitus, coronary heart disease, heart failure, pre-existing chronic pulmonary disease)~* Confirmed SARS-CoV infection~* Radiographic evidence compatible with Covid-19 pneumonia (X-ray/CT scan, etc.)~* Signed Informed Consent Form~II (second step; indication for intervention):~* CRP ≥50mg/L plus 3 out of the following 5 criteria need to be fulfilled:~* Respiration Rate ≥25~* SpO2 \<93% (on ambient air)~* PaO2 \<65 mmHg~* Persistent or increasing dyspnoea as defined by a one point increase on the mMRC dyspnoea scale (over 1 hour)~* Persistent or increasing oxygen demand (over 1 hour)~Exclusion Criteria:~I (first step):~* Patients \>80 years of age~* Patient included in any other interventional trial~* Indication for imminent or immediate transfer to ICU~* Treatment with TCZ (or other anti-IL-6R treatment) within 4 weeks prior to baseline~* Uncontrolled bacterial superinfection according to investigator~* History of severe allergic reaction to TCZ~* History of diverticulitis requiring antibiotic treatment or history of colon perforation~* History of primary immunodeficiency (e.g. CVID) or progressing malignancy~* History of chronic liver disease (\>Child-Pugh A, or according to investigator)~II (second step; contraindication for intervention):~* Alanine transaminase/aspartate transaminase (ALT/AST) \>5 times of the upper limit of normal~* Hemoglobin \<80 g/L~* Leukocytes \<2.0 G/L~* Absolute neutrophil count \<1.0 G/L~* Platelets \<50 G/L

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Actemra (Type: EXPERIMENTAL): Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.

Based on this trial design, predict the completion outcome and termination type (if applicable).